Boston Scientific (BSX) Net Margin (2009 - 2026)

Boston Scientific (BSX) has 18 years of Net Margin data on file, last reported at 25.77% in Q1 2026.

• For the quarter ending Q1 2026, Net Margin rose 1132.0% year-over-year to 25.77%; the trailing twelve-month figure through Mar 2026 stood at 17.29% (up 572.0% YoY), and the FY2025 full-year result was 14.44%, up 337.0% from the prior year.
• Net Margin improved to 25.77% in Q1 2026, from 12.71% in the prior quarter.
• In the past five years, Net Margin ranged from a high of 25.77% in Q1 2026 to a low of 3.21% in Q1 2022.
• A 5-year average of 11.29% and a median of 12.39% in 2024 frame the typical range for Net Margin.
• Across the five-year window, Net Margin tumbled 868 bps in 2022 and jumped 1132 bps in 2026, its largest moves.
• Tracing BSX's Net Margin over 5 years: stood at 3.89% in 2022, then soared by 249 bps to 13.56% in 2023, then fell by 9 bps to 12.39% in 2024, then rose by 3 bps to 12.71% in 2025, then surged by 103 bps to 25.77% in 2026.
• Business Quant data shows BSX's Net Margin at 25.77% in Q1 2026, 12.71% in Q4 2025, and 14.91% in Q3 2025.